Intellectual Property And Other Contractual Issues In Cooperative Research And Development Agreements (CRADAs): Part II
Matthew W. SagalAlliance Management Group, Senior Manager, Marblehead, MA, USAGene SlowinskiRutgers University, Director, Strategic Alliance Research, Newark, NJ, USAKenneth B. FreeseLos Alamos National Laboratories, Manager, Intellectual Asset StrategiesSteven FergusonOffice of Technology Transfer, National Institutes of Health, Deputy Director, Licensing and Entrepreneurship, Rockville, MD, USA This review of Cooperative Research and Development Agreements (CRADAs) is being […]
Shionogi/Purdue Strategic Discovery Alliance With Synchronicity And Serendipity—Case Study Of Open Innovation
Eiichi YamaguchiShionogi & Co., Ltd., Head of Licensing, General Manager, Osaka, Japan The utilization of open innovation (Chesbrough, 20041) for two companies will affect the long-term corporate strategies at both companies. Even prior to the term “open innovation,” Shionogi & Co., Ltd. licensed MS Contin® & OxyContin®, from Mundipharma K.K., the Japanese affiliate of Purdue […]
A Review Of The LES (USA & Canada) 2007/2008 BioPharmaceutical Royalty Rate And Deal Terms Survey
Steven RenwickPharmaVentures Ltd, Consultant, Oxford, UK James A. McCarthyCLP, EGEN, Inc., Senior Vice President, Corporate Development, Huntsville, AL, USA Intellectual property valuation in the healthcare sector is often achieved through a combination of discounted cash flow (DCF) and net present value (NPV) calculations, supported by benchmarking based on publicly available deal information. Published total deal […]
Recent U.S. Decisions And Developments Affecting Licensing – September 2009
Brian BrunsvoldFinnegan, Henderson, Farabow, Garrett & Dunner, LLP, Attorney, Washington, D.C., USA John C. PaulFinnegan, Henderson, Farabow, Garrett & Dunner, LLP, Attorney, Washington, D.C., USA ATTENDING U.S. TRADE SHOWS CAN SUBJECT A FOREIGN COMPANY TO THE JURISDICTION OF THE U.S. COURT AT THAT LOCATION To avoid an unfair result or undue burden on defendants, the […]
Negotiating Pharmaceutical Licensing Deal Structures: Confrontation or Common Ground?
Michael J. MartinMicroDose Therapeutx, Vice President, Licensing and Business Development, Monmouth Junction, NJ, USA Start your engines and look for the checkered flag! Lets’s face it, product and technology licensing negotiations between pharmaceutical and biotechnology companies are challenging, difficult and protracted. From initiating a transaction to ultimate contract, it can take more than a year, […]
Technology Transfer Between Academy And Industry – A Comparison Of The Situation In Germany And United Kingdom
Meital WernerMunich, Germany Heinz Goddar, PhDBoehmert & Boehmert, Patent Attorney, Munich, Germany The paper will explore the legal relationship between industry, academia and government in research collaboration and technology transfer in Germany in comparison to the UK and will raise the questions, to which extent the recent legal changes in Germany have actually improved the […]
Intellectual Property, File-Sharing and Privacy: The Challenge Is On The Internet
Luciano DaffarraLawyer, Daffarra d’Addio & Partners, Milano, Italy This article represents a synthetic work meant to help readers understand the main problems concerning the protection of intellectual works over the Internet. Far be it from exhausting all the aspects of this matter, nevertheless it aims to establish some “landmarks” that may possibly show some ways […]
The Valuation Of Drug Development Project – Part 1
Sangeeta PuranMayer Brown International, Senior Associate, London, UK Overview Earlier in March, 2009, the author completed a study examining the methods used to value drug development programmes. The study was conducted by interviewing individuals over a period of four months in the UK from a representative sample of twelve leading industry participants, including small biotech […]
Software & Valuation In The Information Society Part Four: The Software Inventory Valuation—TOV (MV)
Dwight OlsonCLP, LESI Copyright Committee, V3Data, Principal, San Diego, CA, USA The traditional valuation metrics that apply to physical technology governed by patents do not adequately work for the valuation of software not protected by patents but rather governed by privacy, trade secrecy, and copyright. Only a small portion of commercially available software is covered […]
Biotech Survival Guide: Successfully Navigating the Downturn
Roland Andersson, PhDLeerink Swann, Senior Managing Director, Boston, MA, USA Frank Deane, PhDLeerink Swann, Engagement Manager, Boston, MA, USA Not all hope is lost. Biotechs that adapt to the current market and capital realities and focus on the most value creation activities will be able to survive and excel once market conditions improve. Biotechs are […]